# Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

Source: https://onco.cc/trials/nct07150091/  
OnCo record `nct07150091` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Belantamab mafodotin, Nirogacestat, Lenalidomide in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM is a phase 1/2 interventional study registered as NCT07150091 by GlaxoSmithKline, with 20 participants enrolled, started 2022-07-19 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, Nirogacestat, Lenalidomide, Dexamethasone. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT07150091
- Phase: 1/2
- Setting: A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 6 - Belantamab Mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone in Combination
- Sponsor: GlaxoSmithKline
- Enrolled: 20
- Outcomes: DE Phase: Number of Participants With Dose Limiting Toxicities (DLTs): 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone 1 participants vs 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone 2 participants; DE Phase: Overall Response Rate (ORR): 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone 40% vs 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone 70%

## Sources

- ClinicalTrials.gov NCT07150091: https://clinicaltrials.gov/study/NCT07150091

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Antiemetics for chemotherapy-induced nausea and vomiting](https://onco.cc/technologies/antiemetic-therapy/), [Gamma-secretase inhibitors](https://onco.cc/technologies/gamma-secretase-inhibitors/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Belantamab mafodotin](https://onco.cc/drugs/belantamab-mafodotin/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Nirogacestat](https://onco.cc/drugs/nirogacestat/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07150091.json